Influence of bisphosphonates on alveolar bone density: A histomorphometric analysis

Brazilian Oral Research

Volumn 24, Issue 3, 2010, Pages 309-315

  Santamaria Júnior, Milton ^a   Fracalossi, Ana Carolina Cuzzuol ^a   Consolaro, Maria Fernanda Martins Ortiz ^a   Consolaro, Alberto ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Alendronate; Alveolar bone loss; Bone density; Diphosphonates

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ANIMAL; ARTICLE; BONE DENSITY; DRUG EFFECT; IMAGE PROCESSING; MALE; OSTEOCLAST; RANDOMIZATION; RAT; WISTAR RAT;

ALENDRONATE; ANIMALS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; OSTEOCLASTS; RANDOM ALLOCATION; RATS; RATS, WISTAR;

EID: 77957956290     PISSN: 18068324     EISSN: 18073107     Source Type: Journal    
DOI: 10.1590/S1806-83242010000300009     Document Type: Article

References (30)

1. Fleisch H, Russell RG, Straumann F. Effect of pyrophosphate on hydroxyapatite and its implication in calcium homeostasis. Nature. 1966 Nov 26; 212(5065):901-3.
2. Bisaz S, Russell RG, Fleisch H. Isolation of inorganic pyrophosphate from bovine and human teeth. Arch Oral Biol. 1968 Jun;13(6):683-96.
3. Fleisch H, Russell RG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science. 1969 Sep 19;165(899):1262-4.
4. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998 Feb;19(1):80-100.
5. Rodan GA. Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol. 1998;38:375-88.
6. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000 Mar 1;88(5):1082-90.
7. Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer. 2001 Apr 1;91(7):1191-200.
8. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006 May 16;144(10):753-61.
9. Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6222s-30s.
10. Hughes DE, Macdonald BR, Russell RG, Gowen M. Inhibition of Osteoclasts-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest. 1989 Jun;83(6):1930-5.
11. Vitté C, Fleisch H, Guenther HL. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology. 1996 Jun;137(6):2324-33.
12. Anbinder AL, Prado FA, Prado MA, Balducci I, Rocha RF. The influence of ovariectomy, simvastatin and sodium alendronate on alveolar bone in rats. Braz Oral Res. 2007 Jul-Sep;21(3):247-52.
13. Chaiamnuay S, Saag KG. Postmenopausal osteoporosis. What have we learned since introduction of bisphosphonates? Rev Endocr Metab Disord. 2006 Jun;7(1-2):101-12.
14. nd ed. Philadelphia: Lippincott Company; 1963. Chapter 1, Breeding of the rat;p. 1-17.
15. nd ed. Barcelona: Salvat; 1971.
16. Ott SM. Clinical effects of bisphosphonates in involutional osteoporosis. J Bone Miner Res. 1993 Dec;8 Suppl 2:S597-606.
17. Storm T, Steiniche T, Thamsborg G, Melsen F. Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. J Bone Miner Res. 1993 Feb; 8(2):199-208.
18. Boyce RW, Paddock CL, Gleason JR, Sletsema WK, Eriksen EF. The effects of risedronate on canine cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling site. J Bone Minerv Res. 1995 Feb;10(2):211-21.
19. Russell RG, Rogers MJ. Bisphosphonates: from the laboratry to the clinic and back again. Bone. 1999 Jun; 25(1):97-106.
20. Van Beek E, Pieterman E, Cohen L, Löwik C, Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun. 1999 Oct 14; 264(1):108-11.
21. Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics. 2007 Mar;119 Suppl 2:S150-62.
22. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem. 1996;65:241-69.
23. Zhang D, Udagawa N, Nakamura I, Murakami H, Saito S, Yamasaki K, et al. The small GTP-biding protein, Rho p21, is involved in bone resorption by regulating cytoskeletal organization in osteoclasts. J Cell Sci. 1995 Jun;108(Pt6):2285-92.
24. Fernandes MI, Gaio EJ, Oppermann RV, Rados PV, Rosing CK. Comparison of histometric and morphometric analyses of bone height in ligature-induced periodontitis in rats. Braz Oral Res. 2007 Jul-Sep;21(3):216-21.
25. Tani-Ishii N, Minamida G, Saitoh D, Chieda K, Omuro H, Sugaya A, et al. Inhibitory effects of incadronate on the progression of rat experimental periodontitis by Porphyromonas gingivalis infection. J Periodontol. 2003 May; 74(5):603-9.
26. Weinreb M, Quartuccio H, Seedor JG, Aufdemorte TB, Brunsvold M, Chaves E, et al. Histomorphometrical analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkey. J Periodont Res. 1994 Jan;29(1):35-40.
27. Reddy MS, Weatherford TW 3rd, Smith CA, West BD, Jeffcoat MK, Jacks TM.. Alendronate treatment of naturallyoccurring periodontitis in beagle dogs. J Periodontol. 1995 Mar;66(3):211-7.
28. Olson HM, Hagen A. Inhibition of post-extraction alveolar ridge resorption in rats by dichloromethane diphosphonate. J Periodontal Res. 1982 Nov;17(6):669-74.
29. Lepola VT, Hannuniemi R, Kippo K, Lauren L, Jalovaara P, Vaananen HK. Long-term effects of clodronate on growing rat bone. Bone. 1996 Feb; 18(2):191-6.
30. Erratum in: Bone 1996 Aug; 19(2):205